News

Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Novo Nordisk announces CEO transition as share price slips
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and ...
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
Here’s how much extra weight is lost with Zepbound over Wegovy
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Here’s Why Polen Focus Growth Strategy Exited Novo Nordisk A/S (NVO)
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...